With a net profit margin of 21.83%, Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable American Stocks to Buy in 2026.
Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend remains one of its biggest attractions for income-focused investors.
Johnson & Johnson (NYSE:JNJ) announced on June 15 that it would invest over $1 billion to build a contact lens manufacturing facility in Jacksonville, Florida. Scheduled to be fully operational in 2028, the plant will add manufacturing, packaging, and distribution capacity for the company’s market-leading Acuvue contact lenses. The investment includes the construction of a distribution facility, plus the installation of manufacturing and packaging technologies.
The investment in Jacksonville is part of Johnson & Johnson’s previously announced plan to invest $55 billion in US manufacturing, R&D, and technology, through early 2029. The company had already invested around $12 billion under the expansion plan by the end of 2025.
Joaquin Duato, Chairman and CEO of Johnson & Johnson, commented:
“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world. By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our U.S. supply chain while helping more people see better and live better. This commitment reflects the confidence we have in our people, our technology, and our more than 40-year legacy of advancing eye health globally.”
Guinness Global Equity Income Fund stated the following regarding Johnson & Johnson (NYSE:JNJ) in its Q1 2026 investor letter:
“Johnson & Johnson (NYSE:JNJ) was the Fund’s top-performing stock in Q1 2026, rising 18.7% as markets gained confidence that the company has been effectively replacing revenues of Stelara, a drug that accounted for more than 10% of sales at its peak, but ‘loss of exclusivity’ led to numerous biosimilar launches in 2025. That confidence was fuelled by a very solid earnings print with which the firm reported full-year sales growth of 6%, despite a 7.5 percentage point headwind from Stelara’s loss of exclusivity. Organic sales growth accelerated significantly, rising from 3.7% in Q3 (and 2.4% in Q2) to 7.9% in Q4. Performance was broad-based, with strong momentum across a number of key drugs within the firm’s pharma division, with Tremfya (Crohn’s disease) and Darzalex (Myeloma) the stand-outs. Alone, these drugs were able to provide $4.2bn in sales growth, nearly fully offsetting the $4.3bn decline from Stelara. The remaining drugs in the pharma portfolio were able to grow another $3.6bn, a 6% contribution to the overall growth of the pharma division. MedTech was similarly encouraging, with sales ahead of consensus by 40 basis points and strength across Orthopaedics (recently spun out), Surgery, and Vision, supported by the firm’s recent Shockwave acquisition. Importantly, management reiterated solid 2026 guidance at 5.9% (at the mid-point), and reiterated confidence in achieving the upper end of its 5-7% long-term sales growth target, with a credible path to double-digit growth later in the decade, benefitting from the roll-off of patent cliff headwinds…” (Click here to read the full text)
While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 14 Best S&P 500 Stocks to Buy Now According to Analysts and 10 Most Profitable Energy Stocks to Buy Now
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center